Clinical Trials

    Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial (LoTam)

    Investigator: Sindhu Nair

    Study Coordinator: Misbah Baloch

    Status: Enrolling

    ClinicalTrials.gov Number: NCT06671912

    Phone: 713.790.3311

    Protocol Number: PRO00040327

    Description


    This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the growth of some breast tumors that need estrogen to grow. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme.